Bioventus (US.BVS)
资本配置审计 · 期间： 2013 – 2026
核心指标
US.BVS · 同比： 2026 H1 vs 2025 H1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 94.7% | ↑ |
| ROE | 16.0% | ↑ |
| Cash Conversion | 78.8% | ↓ |
| D/E Ratio | 1.09 | ↑ |
| Gross Margin | 68.9% | → |
US.BVS (Bioventus) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY --------------------------- FCF Conversion 94.7% ↑ ROE 16.0% ↑ Cash Conversion 78.8% ↓ D/E Ratio 1.09 ↑ Gross Margin 68.9% →
核心指标
US.BVS (Bioventus) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY---------------------------FCF Conversion 94.7% ↑ROE 16.0% ↑Cash Conversion 78.8% ↓D/E Ratio 1.09 ↑Gross Margin 68.9% →免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies